Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2023
Historique:
medline: 3 10 2023
pubmed: 4 9 2023
entrez: 4 9 2023
Statut: ppublish

Résumé

It has been proposed that physical activity (PA) could prevent cognitive decline. To evaluate the association between changes in PA and changes in cognitive function in a cohort of adults with metabolic syndrome. Longitudinal observational study including 5,500 adults (mean age 65 years, SD = 5; women = 49.3% ) with metabolic syndrome. Participants underwent physical activity measurements and cognitive evaluation at baseline and at two-years of follow-up. PA was quantified using the Minnesota questionnaire-shortened version. Cognitive function was evaluated using a battery of tests: Mini-Mental Test Examination, Clock Drawing Test, Trail Making Test A and B, Verbal Fluency Test, and Digit Span. The primary outcome was two-year change in cognition, measured through the Global Composite Score (GCS) of all neuropsychological tests. Multivariable-adjusted linear regression models were fitted with baseline PA and their changes as the main exposures and changes in cognitive function as the outcome. No significant association was found between PA levels (or their changes) in the GCS of cognitive function. A greater increase in PA levels was associated with a more favorable two-year change in the Trail Making Test A (Q4 versus Q1: b = - 2.24s, 95% CI -4.36 to -0.12s; p-trend = 0.020). No significant association was found for other neuropsychological test. Our results do not support an association between increases in PA and the evolution of the global cognitive function at two-year in an intervention trial which included PA promotion in one of its two randomized arms, but they suggested a possible beneficial effect of PA on attentional function in older adults.

Sections du résumé

BACKGROUND
It has been proposed that physical activity (PA) could prevent cognitive decline.
OBJECTIVE
To evaluate the association between changes in PA and changes in cognitive function in a cohort of adults with metabolic syndrome.
METHODS
Longitudinal observational study including 5,500 adults (mean age 65 years, SD = 5; women = 49.3% ) with metabolic syndrome. Participants underwent physical activity measurements and cognitive evaluation at baseline and at two-years of follow-up. PA was quantified using the Minnesota questionnaire-shortened version. Cognitive function was evaluated using a battery of tests: Mini-Mental Test Examination, Clock Drawing Test, Trail Making Test A and B, Verbal Fluency Test, and Digit Span. The primary outcome was two-year change in cognition, measured through the Global Composite Score (GCS) of all neuropsychological tests. Multivariable-adjusted linear regression models were fitted with baseline PA and their changes as the main exposures and changes in cognitive function as the outcome.
RESULTS
No significant association was found between PA levels (or their changes) in the GCS of cognitive function. A greater increase in PA levels was associated with a more favorable two-year change in the Trail Making Test A (Q4 versus Q1: b = - 2.24s, 95% CI -4.36 to -0.12s; p-trend = 0.020). No significant association was found for other neuropsychological test.
CONCLUSION
Our results do not support an association between increases in PA and the evolution of the global cognitive function at two-year in an intervention trial which included PA promotion in one of its two randomized arms, but they suggested a possible beneficial effect of PA on attentional function in older adults.

Identifiants

pubmed: 37661880
pii: JAD230105
doi: 10.3233/JAD-230105
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-899

Auteurs

Teresa Rognoni (T)

Department of Neurology, Clínica Universidad de Navarra, Madrid, Spain.

Marta Fernández-Matarrubia (M)

Department of Neurology, Marqués de Valdecilla University Hospital, Santander, Spain.

Miguel Ángel Martinez-González (MÁ)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Jordi Salas-Salvadó (J)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain.
Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain.

Dolores Corella (D)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Olga Castañer (O)

Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

J Alfredo Martínez (JA)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain.
Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.

Ángel M Alonso-Gómez (ÁM)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Bioaraba Health Research Institute, Cardiovascular, Respiratory and Metabolic Area; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.

Enrique Gómez-Gracia (E)

Department of Preventive Medicine and Public Health, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, Málaga, Spain.

Jesús Vioque (J)

Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Instituto de Investigación Sanitaria y Biomédica de Alicante, Universidad Miguel Hernández (ISABIAL-UMH).Alicante, Spain.

Dora Romaguera (D)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), HealthResearch Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.

José López-Miranda (J)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

Ramón Estruch (R)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Internal Medicine, Institut de I'nvestigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Francisco J Tinahones (FJ)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Endocrinology, Virgen de la Victoria Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA). University of Málaga, Málaga, Spain.

José Manuel Santos-Lozano (JM)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain.

Lluis Serra-Majem (L)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria and Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas de Gran Canaria, Spain.

Naomi Cano Ibañez (N)

Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.

Josep A Tur (JA)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands-IUNICS, Palma de Mallorca, Spain.

Rafael Micó Pérez (R)

Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Institute of Biomedicine (IBIOMED), University of León, León, Spain.

Xavier Pintó (X)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain.

Miguel Delgado-Rodríguez (M)

Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Division of Preventive Medicine, Faculty of Medicine, University of Jaén, Jaén, Spain.

María Ortiz Ramos (M)

Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Josep Vidal (J)

Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Clotilde Vázquez (C)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Endocrinology and Nutrition, Hospital Fundación Jiménez Díaz, Instituto de Investigaciones Biomédicas IISFJD, University Autónoma, Madrid, Spain.

Lidia Daimiel (L)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.
Departamento de Ciencias Farmacéuticas y de la Salud, Faculty de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.

Emilio Ros (E)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.

Nuria Goñi-Ruiz (N)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Servicios de Atención Primaria, Navarra Regional Health Service (Osasunbidea), Pamplona, Spain.

Nancy Babio (N)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain.
Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain.

José V Sorlí (JV)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Helmut Schröder (H)

Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Antonio García-Rios (A)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

Laura Compañ-Gabucio (L)

Instituto de Investigación Sanitaria y Biomédica de Alicante, Universidad Miguel Hernández (ISABIAL-UMH).Alicante, Spain.

Julia Warnberg (J)

Department of Nursing, School of Health Sciences University of Malaga, Spain.
Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.

M Ángeles Zulet (MÁ)

IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain.

Alice Chaplin (A)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), HealthResearch Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.

Emilio Sacanella (E)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Internal Medicine, Institut de I'nvestigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Amira Bouzalmate-Hajjaj (A)

Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.

Lucas Tojal-Sierra (L)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Bioaraba Health Research Institute, Cardiovascular, Respiratory and Metabolic Area; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.

Miguel Damas-Fuentes (M)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Endocrinology, Virgen de la Victoria Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA). University of Málaga, Málaga, Spain.

Zenaida Vázquez (Z)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.

Carlos Gómez-Martínez (C)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain.
Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain.

Carmen Saiz (C)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Mireia Malcampo (M)

Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.

Ana M Ortiz-Morales (AM)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

Vanessa Martínez-Avilés (V)

Centro de Salud Raval de Elche, Alicante, Spain.

Jesús García-Gavilan (J)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain.
Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain.

Itziar Abete (I)

IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain.

Montserrat Fitó (M)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.
Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.

Estefanía Toledo (E)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH